Intervention not reported
Severe adverse events: raised amylase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised amylase (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised triglycerides · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised triglycerides (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: neutropenia · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: neutropenia (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: rash · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT) · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Raised cholesterol · antiretroviral‐naïve individuals
The intervention showed no clear difference in raised cholesterol (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · antiretroviral‐naïve individuals
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression to AIDS · antiretroviral‐naïve individuals
The intervention showed no clear difference in progression to AIDS (moderate certainty).
1 finding from 1 review
Intervention not reported
All severe adverse events · antiretroviral‐naïve individuals
It is very uncertain whether the intervention changes all severe adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation rate · antiretroviral‐naïve individuals
The intervention showed no clear difference in discontinuation rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in CD4 count · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Severe adverse events: central nervous system · antiretroviral‐naïve individuals
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
Intervention not reported
a. BMI (kg/m2) · obese children and adolescents
1 finding from 1 review
Intervention not reported
Adverse events a. Serious adverse events b. Discontinuation of trial because of adverse events · obese children and adolescents
The intervention showed no clear difference in adverse events a. Serious adverse events b. Discontinuation of trial… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life 3 questionnaires (1 trial) and SF‐36 (1 trial) · obese children and adolescents
1 finding from 1 review
Intervention not reported
All‐cause mortality · obese children and adolescents
1 finding from 1 review
Intervention not reported
Morbidity · obese children and adolescents
1 finding from 1 review
Intervention not reported
Socioeconomic effects · obese children and adolescents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found